

Variant: NM_000535.7(PMS2):c.1144+1G>A

Version: 2.0

CA009232 [↗](#)

162508 (ClinVar) [↗](#)

Gene: PMS2 (HGNC:5395)

Condition: colorectal cancer, hereditary nonpolyposis, type 4 (MONDO:0013699)

Inheritance Mode: Autosomal dominant inheritance

UUID: 399b7542-9fcc-474f-9408-99aa3c9f8663

Approved on: 2024-09-18

Published on: 2025-08-07

HGVS expressions

NM_000535.7:c.1144+1G>A

NM_000535.7(PMS2):c.1144+1G>A
NC_000007.14:g.5989799C>T
CM000669.2:g.5989799C>T
NC_000007.13:g.6029430C>T
CM000669.1:g.6029430C>T
NC_000007.12:g.5995956C>T
NG_008466.1:g.24308G>A
ENST00000699814.2:c.*540+1G>A
ENST00000699840.2:c.1141+1G>A
ENST00000699930.2:c.1036+1G>A
ENST00000406569.8:c.1144+1G>A
ENST00000644110.2:c.*738+1G>A
ENST00000699752.1:c.988+2174G>A
ENST00000699753.1:c.*565+1G>A
ENST00000699754.1:c.946+1G>A
ENST00000699755.1:c.*543+1G>A
ENST00000699756.1:c.*731+1G>A
ENST00000699757.1:c.*401+1G>A
ENST00000699758.1:c.*401+1G>A
ENST00000699759.1:n.1998+1G>A
ENST00000699760.1:c.826+1G>A
ENST00000699761.1:c.739+1G>A
ENST00000699762.1:c.571+1G>A
ENST00000699763.1:c.*234+1G>A
ENST00000699764.1:c.1144+1G>A
ENST00000699765.1:c.*240+1G>A
ENST00000699766.1:c.1144+1G>A
ENST00000699767.1:c.1144+1G>A
ENST00000699768.1:c.1144+1G>A
ENST00000699811.1:c.739+1G>A
ENST00000699813.1:n.1257+1G>A
ENST00000699814.1:c.767+1G>A
ENST00000699815.1:c.*636+1G>A
ENST00000699816.1:c.739+1G>A
ENST00000699817.1:c.*738+1G>A
ENST00000699818.1:c.739+1G>A

ENST00000699819.1:c.*301+1G>A
ENST00000699820.1:c.1144+1G>A
ENST00000699821.1:c.739+1G>A
ENST00000699822.1:c.*596+1G>A
ENST00000699823.1:c.739+1G>A
ENST00000699824.1:c.*647+1G>A
ENST00000699825.1:c.583+2174G>A
ENST00000699826.1:c.*543+1G>A
ENST00000699827.1:c.976+1G>A
ENST00000699828.1:c.*234+1G>A
ENST00000699829.1:c.*645+1G>A
ENST00000699830.1:c.*543+1G>A
ENST00000699833.1:n.2916+1G>A
ENST00000699837.1:c.739+1G>A
ENST00000699838.1:c.*1044+1G>A
ENST00000699839.1:c.1330+1G>A
ENST00000699840.1:c.1141+1G>A
ENST00000699916.1:c.*401+1G>A
ENST00000699917.1:c.*593+1G>A
ENST00000699918.1:c.*645+1G>A
ENST00000699919.1:c.*731+1G>A
ENST00000699920.1:c.*780+1G>A
ENST00000699928.1:c.988+2174G>A
ENST00000699929.1:c.*445+1G>A
ENST00000699930.1:c.1036+1G>A
ENST00000699931.1:n.2572+1G>A
ENST00000699932.1:c.*362+1G>A
ENST00000699933.1:n.1125G>A
ENST00000699951.1:c.*240+1G>A
ENST00000699952.1:c.803+7527G>A
ENST00000699953.1:c.*251+1G>A
ENST00000699954.1:c.*445+1G>A
ENST00000265849.12:c.1144+1G>A
ENST00000642292.1:c.739+1G>A
ENST00000642456.1:c.739+1G>A
ENST00000643595.1:c.*543+1G>A
ENST00000644110.1:c.826+1G>A
ENST00000265849.11:c.1144+1G>A
ENST00000382321.5:c.804-6808G>A
ENST00000406569.7:n.1144+1G>A
ENST00000441476.6:c.826+1G>A
ENST00000469652.1:n.63-6894G>A
NM_000535.5:c.1144+1G>A
NR_003085.2:n.1226+1G>A
NM_000535.6:c.1144+1G>A
NM_001322003.1:c.739+1G>A
NM_001322004.1:c.739+1G>A
NM_001322005.1:c.739+1G>A
NM_001322006.1:c.988+2174G>A
NM_001322007.1:c.826+1G>A
NM_001322008.1:c.826+1G>A
NM_001322009.1:c.739+1G>A

NM_001322010.1:c.583+2174G>A
NM_001322011.1:c.211+1G>A
NM_001322012.1:c.211+1G>A
NM_001322013.1:c.571+1G>A
NM_001322014.1:c.1144+1G>A
NM_001322015.1:c.835+1G>A
NR_136154.1:n.1231+1G>A
NM_001322003.2:c.739+1G>A
NM_001322004.2:c.739+1G>A
NM_001322005.2:c.739+1G>A
NM_001322006.2:c.988+2174G>A
NM_001322008.2:c.826+1G>A
NM_001322009.2:c.739+1G>A
NM_001322010.2:c.583+2174G>A
NM_001322011.2:c.211+1G>A
NM_001322012.2:c.211+1G>A
NM_001322013.2:c.571+1G>A
NM_001322014.2:c.1144+1G>A
NM_001322015.2:c.835+1G>A
NM_001322007.2:c.826+1G>A

Likely Pathogenic

Met criteria codes **3**

PVS1_Strong PP4 PM2_Supporting

Evidence Links **0**

Expert Panel

[InSiGHT Hereditary Colorectal Cancer/Polyposis VCEP](#)

Criteria Specification Information

[Criteria Specification:](#) *ClinGen InSiGHT Hereditary Colorectal Cancer/Polyposis Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for PMS2 Version 1.0.0*

[Criteria Specification Approval History](#)

[Criteria Specifications for this VCEP](#)

Evidence submitted by expert panel

InSiGHT Hereditary Colorectal Cancer/Polyposis VCEP

The NM_000535.7:c.1144+1G>A p.(?) variant in PMS2 occurs within the canonical splice donor site (+1) of intron 10. It is predicted to result in an in-frame exon skipping and the altered region is critical to protein function (PVS1_Strong). The variant was detected in one CRC/Endometrial MSI-H tumour using a standard panel of 5-10 markers and/or loss of MMR protein expression consistent with the variant location (PP4). This variant is extremely rare (2 in 267958 alleles) in gnomAD using the non cancer dataset and also the gnomAD v4.1 Grpmax AF is 6.856e-7 (PM2_Supporting). In summary, this variant meets the criteria to be classified as likely pathogenic for Lynch-Syndrome based on the ACMG/AMP criteria applied, as specified by the ClinGen InSiGHT Hereditary Colorectal Cancer/ Polyposis VCEP: PVS1_STR, PM2_SUP, PP4 (VCEP specifications version 1)

Met criteria codes

PVS1_Strong



The variant occurs within the canonical splice donor site (+1) of intron 10. It is predicted to result in an in-frame exon skipping and the altered region is critical to protein function (PVS1_Strong).

PP4



The variant was detected in one CRC/Endometrial MSI-H tumour using a standard panel of 5-10 markers and/or loss of MMR protein expression consistent with the variant location (PP4).

PM2_Supporting



This variant is extremely rare (2 in 267958 alleles) in gnomAD using the non cancer dataset (PM2_Supporting) (Update: gnomAD v4.1 Grpmax AF = 6.856e-7)

Curation History [↗](#)

Showing 1 to 2 of 2 rows

--

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.